Arginine Hydrochloride

Summary

Arginine Hydrochloride (CHEMBL1200381) is an approved small molecule (ATC B05XB01); indicated across 6 conditions including pituitary dwarfism and hepatocellular carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B05XB01
• Indications: 6 conditions
• Clinical trials: 11
• Chemistry: 210.66 Da · C6H15ClN4O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200381
Name	Arginine Hydrochloride
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	66250
ATC	B05XB01
Molecular formula	C6H15ClN4O2
Molecular weight	210.66
InChIKey	KWTQSFXGGICVPE-WCCKRBBISA-N

SMILES: C(C[C@@H](C(=O)O)N)CN=C(N)N.Cl

IUPAC name: (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;hydrochloride

Also known as: Arginine hcl, Arginine hydrochloride, L-arginine hcl, L-arginine hydrochloride, NSC-203450, NSC-7914, R-gene 10, ARGININE HYDROCHLORIDE, arginine hydrochloride

Patent coverage: 5,629 distinct patent families (17,517 SureChEMBL compound mentions), from 5 matched compound structure(s). One matched structure accounts for 17,431 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pituitary dwarfism	4	MONDO:0006909	EFO:1001109
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
sickle cell disease	3	MONDO:0011382	MONDO:0011382
neoplasm	3	MONDO:0005070	MONDO:0004992
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
Plasmodium falciparum malaria	2	MONDO:0005920	EFO:0007444

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE3	5
PHASE2	3
PHASE1/PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03274427	PHASE3	UNKNOWN	Treatment of Intermediate-stage Hepatocellular Carcinoma
NCT03278444	PHASE3	UNKNOWN	Treatment of Advanced Hepatocellular Carcinoma
NCT03940053	PHASE3	UNKNOWN	Prevention of Cancer Development and Progression
NCT03950518	PHASE3	UNKNOWN	Novel Treatment of Advanced Hepatocellular Carcinoma
NCT04839354	PHASE3	COMPLETED	Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial
NCT05855330	PHASE2	RECRUITING	Arginine Replacement Therapy in COVID-19
NCT07167693	PHASE1/PHASE2	RECRUITING	Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes
NCT00029731	PHASE2	COMPLETED	Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients
NCT00616304	PHASE2	SUSPENDED	Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria
NCT03031535	PHASE1	COMPLETED	Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers
NCT06248359	Not specified	RECRUITING	Association Between Postoperative Administration of L-Arginine and CSA-AKI

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).